ReviewCurrent topics in behavioral neurosciences2025
Behavioral Neurobiology of Alcohol Addiction: A Decade of Great Challenges, New Hopes, and Hypes.
Review in Current topics in behavioral neurosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over a decade after the first edition of "Behavioral Neurobiology of Alcohol Addiction," this chapter revisits the field at a critical juncture, marked by both persistent challenges and emerging opportunities. We reflect on the translational gap that has stalled the development of new treatments for alcohol use disorder (AUD), despite decades of promising preclinical findings. Particular attention is given to the replicability crisis in animal research, publication biases, and the limited predictive validity of existing models. At the same time, we highlight advances that offer renewed hope, including molecular and circuit-level technologies, AI-driven data analysis, real-world assessments, and new pharmacological candidates, such as GLP-1 agonists and psychedelics. These breakthroughs are considered alongside the increasing recognition of inflammation, pain, and neuroimmune factors as integral to AUD. However, we caution against exaggerated claims and urge the field to avoid oversimplified models, especially those that conflate habits and compulsions. Finally, we argue that neurobiological progress must be complemented by public health strategies aimed at reducing stigma and improving access to care. By fostering empirical rigor, embracing complexity, and maintaining critical self-reflection, addiction science can better align its innovations with real-world clinical and societal needs.
Indexed as
Identifiers
40646424What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.